Fifty Oklahoma teens have been selected as OMRF’s 2019-20 class of Teen Leaders in Philanthropy.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
Two students from the Naval Academy and one from the Air Force Academy participated in the OMRF’s ninth annual Saxon program.
The 2018-19 Teen Leaders in Philanthropy class includes 50 teenagers from 25 high schools across the state.
Eight weeks of research just wrapped up for 14 gifted young scientists.